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Abstract 
Objective: The safety profiles of oral fluoropyrimidines were compared with 5-fluorouracil 
(5-FU) using adverse event reports (AERs) submitted to the Adverse Event Reporting System, 
AERS, of the US Food and Drug Administration (FDA). 
Methods: After a revision of arbitrary drug names and the deletion of duplicated submissions, 
AERs involving 5-FU and oral fluoropyrimidines were analyzed. Standardized official  pharma-
covigilance tools were used for the quantitative detection of signals, i.e., drug-associated adverse 
events,  including  the  proportional  reporting  ratio,  the  reporting  odds  ratio,  the  information 
component given by a Bayesian confidence propagation neural network, and the empirical Bayes 
geometric mean.  
Results: Based on 22,017,956 co-occurrences, i.e., drug-adverse event pairs, found in 1,644,220 
AERs from 2004 to 2009, it was suggested that leukopenia, neutropenia, and thrombocytopenia 
were more frequently accompanied by the use of 5-FU than capecitabine, whereas diarrhea, 
nausea, vomiting, and hand-foot syndrome were more frequently associated with capecitabine. 
The total number of co-occurrences was not large enough to compare tegafur, tegafur-uracil 
(UFT), tegafur-gimeracil-oteracil potassium (S-1), or doxifluridine to 5-FU. 
Conclusion: The results obtained herein were consistent with clinical observations, suggesting 
the usefulness of the FDA’s AERS database and data mining methods used, but the number of 
co-occurrences is an important factor in signal detection. 
Key words: adverse events, AERS, 5-fluorouracil, capecitabine, pharmacovigilance. 
Introduction 
5-Fluorouracil (5-FU) exerts its anticancer effects 
through  the  inhibition  of  thymidylate  synthase  and 
incorporation of its metabolites into RNA and DNA, 
and has been widely used for the treatment of solid 
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tumors for nearly 50 years [1]. In the early 1990s, a 
repetitive  injection  of  5-FU  with  a  biomodulating 
agent, leucovorin (LV) was the standard treatment for 
metastatic colorectal cancer [2, 3]. However, preclini-
cal  evidence  that  increased  exposure  to  5-FU  im-
proves the cytotoxic activity, and the fact that 5-FU 
has a short plasma half-life [4] resulted in the inclu-
sion of continuous infusion in the regimens. Current-
ly, the FOLFIRI or FOLFOX regimen, with or without 
a  targeted  monoclonal  antibody,  is  the  standard 
treatment, consisting of a bolus of 5-FU, the infusion 
of  5-FU/LV,  and  irinotecan  or  oxaliplatin,  respec-
tively [5-8]. One of the most important factors com-
plicating the clinical use of 5-FU is difficulties for pa-
tients, because of the potential for infection, bleeding 
and  thromboembolism  [9,  10],  and/or  higher  treat-
ment  costs  [11-13],  resulting  in  the  development  of 
oral  fluoropyrimidines,  e.g.,  capecitabine,  tegafur, 
tegafur-uracil (UFT), tegafur-gimeracil-oteracil potas-
sium (S-1), and doxifluridine [14-16]. 
 Immediately  after  oral  fluoropyrimidine  de-
velopment, replacement of the 5-FU/LV infusion with 
oral  fluoropyrimidines  was  investigated,  especially 
for  capecitabine;  with  preferable  clinical  outcomes, 
oral fluoropyrimidines now hold great promise and 
they  are  named  the  XELIRI  or  XELOX  regimens 
[17-21].  The  FOLFOX  regimen  was  associated  with 
neutropenia more than the XELOX regimen, whereas 
XELOX was more frequently associated with diarrhea 
and hand-foot syndrome (HFS) [17-20]. However, no 
conclusions  were  obtained  for  adverse  events  with 
relatively low frequencies, including nausea, vomit-
ing,  and  stomatitis  [17-20],  and  the  comparison  be-
tween  the  FOLFIRI  and  XELIRI  regimens  failed  to 
clarify a difference in safety profiles, presumably due 
to  the  low  number  of  participants  [21].  A  recently 
published pooled-analysis of randomized trials with a 
total of 6571 participants demonstrated that the use of 
capecitabine instead of 5-FU resulted in significantly 
less  toxicity  in  terms  of  neutropenia  and  stomatitis 
[22]. In contrast, HFS was more frequently observed 
for capecitabine, but the analysis could not elucidate 
the effect of the replacement on susceptibility to di-
arrhea, nausea and vomiting, due to extensive varia-
tion in the results of trials used for pooled-analysis 
[22].  
 In this study, the safety profiles of oral fluoro-
pyrimidines  were  compared  with  5-FU  using  more 
than a million case reports on adverse events (AERs) 
submitted to the US Food and Drug Administration 
(FDA)  database.  This  database  relies  on  reports  of 
spontaneous  adverse  events  submitted  to  the  FDA 
generated  by  health  professionals,  consumers,  and 
manufacturers; the system is referred to as the Ad-
verse Event Reporting System (AERS). A statistically 
significant association with an adverse event was de-
tected  as  a  signal  by  applying  standardized  official 
pharmacovigilance  methods  [23-29].  Here,  the  ad-
verse events focused on included myelosuppression 
(leucopenia,  neutropenia,  and  thrombocytopenia), 
gastrointestinal toxicity (diarrhea, nausea, and vom-
iting), stomatitis, and HFS. 
Methods 
Data sources 
 Input data for this study were taken from the 
public  release  of  the  FDA’s  AERS  database,  which 
covers  the  period  from  the  first  quarter  of  2004 
through the end of 2009. The data structure of AERS is 
in  compliance  with  international  safety  reporting 
guidance ICH E2B, consisting of 7 data sets: patient 
demographic  and  administrative  information 
(DEMO), drug/biologic information (DRUG), adverse 
events  (REAC),  patient  outcomes  (OUTC),  report 
sources  (RPSR),  drug  therapy  start  and  end  dates 
(THER),  and  indications  for  use/diagnosis  (INDI). 
The  adverse  events  in  REAC  are  coded  using  pre-
ferred terms (PTs) in the Medical Dictionary for Reg-
ulatory  Activities  (MedDRA)  terminology.  Here, 
MedDRA ver. 13.0 was used. 
 Prior to analysis, all drug names were unified 
into  generic  names  by  a  text-mining  approach,  be-
cause AERS permits the registering of arbitrary drug 
names,  including  trade  names  and  abbreviations. 
Spelling  errors  were  detected  by  GNU  Aspell  and 
carefully confirmed by working pharmacists. Foods, 
beverages, treatments (e.g. X-ray radiation), and un-
specified names (e.g. beta-blockers) were omitted for 
this study. Duplicated reports were deleted according 
to the FDA's recommendation of adopting the most 
recent CASE number, resulting in the reduction of the 
number of AERs from 2,231,029 to 1,644,220. The total 
number  of  co-occurrences,  i.e.,  drug-adverse  event 
pairs, in 1,644,220 AERs was 22,017,956.  
Definition of adverse events 
 According to the MedDRA ver. 13.0, leucopenia, 
neutropenia,  thrombocytopenia,  diarrhea,  nausea, 
vomiting, stomatitis and HFS are coded as preferred 
term identifiers PT10024384, PT10029354, PT10043554, 
PT10012735,  PT10028813,  PT10047700,  PT10042128 
and PT10033553, respectively.  
Data mining 
 In pharmacovigilance analyses, data mining al-
gorithms  have  been  developed  to  identify 
drug-associated  adverse  events  as  signals  that  are Int. J. Med. Sci. 2012, 9 
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reported more frequently than expected by estimating 
expected reporting frequencies on the basis of infor-
mation  on  all  drugs  and  all  events  in  a  database 
[23-25]. For example, the proportional reporting ratio 
(PRR) [26], the reporting odds ratio (ROR) [27],  the 
information  component  (IC)  [28], and  the  empirical 
Bayes geometric mean (EBGM) [29] are widely used, 
and  indeed,  the  PRR  is  currently  used  by  the  UK 
Medicines  and  Healthcare  products  Regulatory 
Agency (MHRA), the ROR by the Netherlands Phar-
macovigilance  Centre,  the  IC  by  the  World  Health 
Organization (WHO), and the EBGM by the FDA.  
 All of these algorithms extract decision rules for 
signal  detection  and/or  calculate  scores  to  measure 
the  associations  between  drugs  and  adverse  events 
from a two-by-two frequency table of counts that in-
volve the presence or absence of a particular drug and 
a  particular  event  occurring  in  case  reports.  These 
algorithms, however, differ from one another in that 
the  PRR  and  ROR  are  frequentist  (non-Bayesian), 
whereas the IC and EBGM are Bayesian. In this sec-
tion, only the scoring thresholds used in the present 
study are given, and the reader is referred to review 
articles for more extensive details of each statistical 
test [23-25]. 
 Here, we define how a drug and associated ad-
verse event is classified as a signal, when using each 
statistical test. Using the PRR, a signal is detected, if 
the count of co-occurrences is 3 or more, and the PRR 
is 2 or more with an associated χ2 value of 4 or more 
[26]. For the ROR, a signal is detected, if the lower 
bound  of  the  95%  two-sided  confidence  interval  of 
ROR exceeds 1 [27]. Signal detection using the IC is 
done using the IC025 metric, a criterion indicating the 
lower bound of the 95% two-sided confidence interval 
of the IC, and a signal is detected with the IC025 value 
exceeds  0  [28].  Finally,  the  EB05  metric,  a  lower 
one-sided 95% confidence limit of EBGM [29], is used 
and a signal is detected when EB05 is greater than or 
equal to the threshold value 2. In this study, the ad-
verse events were extracted when at least 1 of 4 indi-
ces met the criteria indicated above. 
Results 
 The total number of co-occurrences with 5-FU 
was  40,284,  and  34,928  for  capecitabine,  320  for 
tegafur, 1,215 for UFT, 1,422 for S-1, and 495 for doxi-
fluridine,  representing  0.183%,  0.159%,  0.001%, 
0.006%, 0.006% and 0.002% of all co-occurrences in the 
database, respectively. In total, 864, 802, 110, 227, 246 
and 168 adverse events were extracted as 5-FU- or oral 
fluoropyrimidine-associated  adverse  events  with 
23,690, 20,290, 200, 773, 861 and 305 co-occurrences, 
respectively. For each of tegafur, UFT, S-1 and doxi-
fluridine, the total number of co-occurrences was not 
large enough to compare with 5-FU.  
 The 5-FU-associated adverse events are listed in 
Table 1, which are ranked according to the number of 
co-occurrences, and the data for capecitabine is listed 
in Table 2. The adverse events commonly found in the 
worst  20  included  neutropenia,  diarrhea,  nausea, 
vomiting,  pyrexia,  pulmonary  embolism,  mucosal 
inflammation,  asthenia,  a  decrease  of  haemoglobin 
level, and sepsis.  
In  Tables  3-6,  the  data  on  capecitabine  was 
compared  with  5-FU  in  terms  of  susceptibility  to 
myelosuppression,  gastrointestinal  toxicity,  stomati-
tis, and HFS, respectively. The statistical metrics sug-
gested 5-FU- and capecitabine-associated leukopenia, 
neutropenia and thrombocytopenia, but the associa-
tion was weaker for capecitabine than 5-FU (Table 3). 
The associations with diarrhea, nausea and vomiting 
were also suggested for both, but it was more note-
worthy for capecitabine than 5-FU (Table 4). The sig-
nals were also detected for stomatitis, but there were 
no statistical differences between 5-FU and capecita-
bine (Table 5). The analysis suggested that HFS oc-
curred more extensively for capecitabine (Table 6). 
Table 1. Adverse events more frequently associated with 
the use of 5-FU. 
N  Adverse event 
1076  Diarrhoea 
774  Vomiting 
715  Nausea 
708  Dehydration 
658  Neutropenia 
631  Pyrexia 
494  Febrile neutropenia 
415  Abdominal pain 
345  Pulmonary embolism 
344  Mucosal inflammation 
342  Asthenia 
328  Thrombocytopenia 
316  Anaemia 
312  Haemoglobin decreased 
306  Hypotension 
277  Leukopenia 
277  Sepsis 
256  Decreased appetite 
252  Pneumonia 
251  White blood cell count decreased 
N: the number of co-occurrences.  
Official PT terms of MedDRA ver. 13.0 are listed. 
The total number of co-occurrences with 5-FU was 40,284, and 864 
adverse events were extracted as 5-FU-associated adverse events 
with 23,690 co-occurrences in total. 
The adverse events were extracted when at least 1 of 4 indices met 
the criteria: the proportional reporting ratio (PRR), the reporting 
odds ratio (ROR), the information component (IC), and the empir-
ical Bayes geometric mean (EBGM). Int. J. Med. Sci. 2012, 9 
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Table 2. Adverse events more frequently associated with 
the use of capecitabine. 
N  Adverse event 
1790  Diarrhoea 
843  Vomiting 
842  Nausea 
694  Dehydration 
626  Death 
500  Disease progression 
490  Pyrexia 
456  Palmar-plantar erythrodysaesthesia syn-
drome 
386  Fatigue 
385  Asthenia 
325  Mucosal inflammation 
305  Abdominal pain 
288  Osteonecrosis 
284  Decreased appetite 
276  Neutropenia 
244  Sepsis 
242  Malignant neoplasm progression 
219  General physical health deterioration 
198  Pulmonary embolism 
191  Haemoglobin decreased 
N: the number of co-occurrences. 
Official PT terms of MedDRA ver. 13.0 are listed. 
The total number of co-occurrences with capecitabine was 34,928, 
and 802 adverse events were extracted as capecitabine-associated 
adverse events with 20,290 co-occurrences in total.  
The adverse events were extracted when at least 1 of 4 indices met 
the criteria: the proportional reporting ratio (PRR), the reporting 
odds ratio (ROR), the information component (IC), and the empir-
ical Bayes geometric mean (EBGM). 
Discussion 
 The efficacy of each regimen is one of the most 
influential factors when the method of cancer chem-
otherapy is chosen from patients; however, there is 
increasing emphasis on assessment of quality of life, 
convenience for and preference of the patients. Some 
questionnaire-based  studies  have  shown  that  oral 
treatment is more preferred, provided that it is not at 
the  expense  of  efficacy  [30-32].  Another  study  sug-
gested that patients prefer the regimen with less tox-
icity and that it is of minor importance whether the 
medication is administrated orally at home or intra-
venously at a hospital [33]. The AERS database covers 
several million case reports on adverse events, and is 
characterized  by  spontaneity.  Despite  some  limita-
tions  inherent  to  spontaneous  reporting,  the  AERS 
database is a rich resource and the data mining tools 
provide  a  powerful  means  of  identifying  potential 
associations  between  drugs  and  adverse  events. 
Pharmacovigilance aims to search for previously un-
known  patterns  and  automatically  detect  important 
signals,  i.e.,  drug-associated  adverse  events,  from 
such a large database. Recently developed data min-
ing  tools,  i.e.,  the  PRR,  ROR,  IC,  and  EBGM,  have 
been successful at detecting signals that could not be 
found  by  individual  case  reviews  and  that  warrant 
further  investigation  together  with  continuous  sur-
veillance [23-29]. These tools are now used routinely 
for  pharmacovigilance,  supporting  signal  detection 
and decision-making at companies, regulatory agen-
cies, and pharmacovigilance centers.  
 
Table 3. Signal detection for 5-FU- and capecitabine-associated myelosuppression. 
    N    PRR 
(χ2) 
  ROR 
(95% two-sided CI) 
  IC 
(95% two-sided CI) 
  EBGM 
(95% one-sided CI) 
Leukopenia                     
5-FU    277    5.282 * 
(952.334) 
  5.323 * 
(4.727, 5.919) 
  2.368 * 
(2.197, 2.540) 
  5.224 * 
(4.720) 
Capecitabine    115    2.520 * 
(103.730) 
  2.526 * 
(2.103, 2.949) 
  1.306 * 
(1.041, 1.570) 
  2.432 * 
(2.081) 
                     
Neutropenia                     
5-FU    658    6.912 * 
(3272.836) 
  6.986 * 
(6.465, 7.507) 
  2.755 * 
(2.643, 2.867) 
  6.808 * 
(6.382) 
Capecitabine    276    3.315 * 
(441.127) 
  3.327 * 
(2.955, 3.700) 
  1.707 * 
(1.535, 1.878) 
  3.241 * 
(2.931) 
                     
Thrombocytopenia                     
5-FU    328    2.749 * 
(360.868) 
  2.758 * 
(2.473, 3.042) 
  1.442 * 
(1.284, 1.599) 
  2.699 * 
(2.463) 
Capecitabine    180    1.735 
(55.060) 
  1.737 * 
(1.500, 1.974) 
  0.782 * 
(0.570, 0.993) 
  1.708 
(1.509) 
N: the number of co-occurrences.  
*: signal detected, and a signal means a drug-associated adverse event (see “Methods” for the criteria of detection).  
Leukopenia, neutropenia, and thrombocytopenia were coded as PT10024384, PT10029354, and PT10043554, respectively. 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric 
mean. Int. J. Med. Sci. 2012, 9 
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Table 4. Signal detection for 5-FU- and capecitabine-associated gastrointestinal toxicity. 
    N    PRR 
(χ2) 
  ROR 
(95% two-sided CI) 
  IC 
(95% two-sided CI) 
  EBGM 
(95% one-sided CI) 
Diarrhea                     
5-FU    1076    3.243 * 
(1625.228) 
  3.256 * 
(3.064, 3.448) 
  1.667 * 
(1.579, 1.754) 
  3.169 * 
(3.013) 
Capecitabine    1790    6.383 * 
(7716.174) 
  6.435 * 
(6.135, 6.736) 
  2.606 * 
(2.537, 2.675) 
  6.104 * 
(5.870) 
                     
Nausea                     
5-FU    715    1.364 
(68.113) 
  1.365 * 
(1.268, 1.463) 
  0.440 * 
(0.333, 0.547) 
  1.355 
(1.274) 
Capecitabine    842    1.865 
(329.449) 
  1.868 * 
(1.744, 1.991) 
  0.881 * 
(0.782, 0.980) 
  1.839 
(1.737) 
                     
Vomiting                     
5-FU    774    2.174 * 
(481.110) 
  2.179 * 
(2.029, 2.329) 
  1.102 * 
(1.000, 1.205) 
  2.143 * 
(2.019) 
Capecitabine    843    2.745 * 
(912.239) 
  2.752 * 
(2.570, 2.935) 
  1.431 * 
(1.332, 1.530) 
  2.689 * 
(2.540) 
Colum headings are identical to Table 3. 
*: signal detected, and a signal means a drug-associated adverse event (see “Methods” for the criteria of detection).  
Diarrhea, nausea, and vomiting were coded as PT10012735 (diarrhoea), PT10028813, and PT10047700, respectively. 
 
Table 5. Signal detection for 5-FU- and capecitabine-associated stomatitis. 
    N    PRR 
(χ2) 
  ROR 
(95% two-sided CI) 
  IC 
(95% two-sided CI) 
  EBGM 
(95% one-sided CI) 
5-FU    193    5.905 * 
(779.160) 
  5.959 * 
(5.169, 6.748) 
  2.517 * 
(2.312, 2.722) 
  5.853 * 
(5.184) 
Capecitabine    174    6.141 * 
(741.267) 
  6.192 * 
(5.331, 7.053) 
  2.567 * 
(2.351, 2.782) 
  6.087 * 
(5.357) 
Colum headings are identical to Table 3. 
*: signal detected, and a signal means a drug-associated adverse event (see “Methods” for the criteria of detection).  
Stomatitis was coded as PT10042128. 
 
Table 6. Signal detection for 5-FU- and capecitabine-associated hand-foot syndrome. 
    N    PRR 
(χ2) 
  ROR 
(95% two-sided CI) 
  IC 
(95% two-sided CI) 
  EBGM 
(95% one-sided CI) 
5-FU    64    6.059 * 
(265.364) 
  6.116 * 
(4.779, 7.452) 
  2.478 * 
(2.124, 2.832) 
  5.952 * 
(4.774) 
Capecitabine    456    50.368 * 
(21762.799) 
  54.596 * 
(49.588, 59.604) 
  5.488 * 
(5.350, 5.626) 
  49.485 * 
(45.787) 
Colum headings are identical to Table 3. 
*: signal detected, and a signal means a drug-associated adverse event (see “Methods” for the criteria of detection).  
Hand-foot syndrome was coded as PT10033553 (palmar-plantar erythrodysaesthesia syndrome). 
 
 
Here, AERs submitted to the FDA’s AERS data-
base were reviewed to compare the safety profiles of 
oral fluoropyrimidines with 5-FU, but the total num-
bers  of  co-occurrences  with  tegafur,  UFT,  S-1  and 
doxifluridine were not large enough for comparisons. 
Previously, the same database and data mining tools 
were used to confirm the adverse events accompanied 
with  the  use  of  the  platinum  agents,  cisplatin,  car-
boplatin, and oxaliplatin [34]. The analysis suggested 
that  these  agents  possibly  cause  nausea,  vomiting, 
acute  renal  failure,  neutropenia,  thrombocytopenia, 
and peripheral sensory neuropathy [34]. In terms of 
susceptibility,  their  rank-order  was  consistent  with 
clinical observations, suggesting the usefulness of the 
AERS  database  and  the  data  mining  method  used 
[34].  Additionally,  the  National  Cancer  Institute 
Common  Terminology  Criteria  for  Adverse  Events, 
NCI-CTCAE, version 4.0 was applied to evaluate the 
susceptibility of 14 anticancer agents to hypersensi-
tivity reactions, and it was found that the number of Int. J. Med. Sci. 2012, 9 
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co-occurrences was an important factor in signal de-
tection [35, 36]. Very recently, this system was applied 
for evaluation of muscular and renal adverse events 
induced  by  the  administration  of  pravastatin, 
simvastatin,  atorvastatin,  or  rosuvastatin,  and  their 
rank-order  of  susceptibility  was  quantitatively  sug-
gested [37]. 
 Comparison of the FOLFOX regimen with the 
XELOX regimen has indicated 5-FU to be more highly 
associated  with  neutropenia  compared  to  capecita-
bine [17-20]. This was proved by a pooled-analysis of 
randomized  trials  [22],  and  again  confirmed  here 
(Table  3).  In  contrast,  clinical  reports  indicated  that 
HFS was more frequently accompanied by the use of 
capecitabine than 5-FU [17-20, 22], and this was also 
consistent  with  the  data  shown  here  (Table  6).  Alt-
hough a pooled-analysis failed to clarify their differ-
ence  in  terms  of  susceptibility  to  diarrhea  [22],  the 
comparisons of two regimens have shown that diar-
rhea was  more  noteworthy for capecitabine [17-20]. 
This was confirmed in the present study, and addi-
tionally,  the  statistical  metrics  suggested  that  cape-
citabine possibly caused nausea and  vomiting more 
frequently  than  5-FU  (Table  4).  For  stomatitis,  a 
pooled-analysis suggested that it occurred more fre-
quently with 5-FU than capecitabine, though the pre-
sent study did not show the same difference (Table 5).  
 In conclusion, the safety profiles of oral fluoro-
pyrimidines  were  compared  with  5-FU  using  AERs 
submitted  to  the  FDA’s  AERS.  Based  on  22,017,956 
co-occurrences found in 1,644,220 AERs from 2004 to 
2009,  it  was  suggested  that  myelosuppression  were 
more frequently accompanied by the use of 5-FU than 
capecitabine,  whereas  gastrointestinal  toxicity  and 
HFS were more frequently associated with capecita-
bine.  The  total  number  of  co-occurrences  was  not 
large enough to be conclusive for tegafur, UFT, S-1 
and doxifluridine. The results obtained herein were 
consistent with clinical  observations, suggesting the 
usefulness  of  the  FDA’s  AERS  database  and  data 
mining  methods  used,  but  the  number  of 
co-occurrences is an important factor in signal detec-
tion.  
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